Natalia S Pellegata Selected Research

Cyclin-Dependent Kinase Inhibitor p27

1/2015	Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4 (MEN4).
3/2013	A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype.
6/2012	Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds.
4/2011	Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas.
7/2007	Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutations and rarely with deletions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Natalia S Pellegata Research Topics

Disease

31	Neoplasms (Cancer) 01/2022 - 09/2004
10	Pheochromocytoma 01/2022 - 07/2007
8	Pituitary Neoplasms (Pituitary Adenoma) 06/2021 - 08/2011
5	Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis) 02/2016 - 07/2007
4	Paraganglioma (Paragangliomas) 01/2022 - 07/2007
4	Neuroendocrine Tumors (Neuroendocrine Tumor) 10/2017 - 10/2010
4	Papillary Thyroid Cancer 01/2005 - 05/2003
3	Acromegaly 12/2020 - 05/2015
3	Hyperplasia 02/2016 - 01/2009
3	Adenoma (Adenomas) 07/2015 - 01/2005
3	Carcinogenesis 08/2012 - 09/2004
2	Thyroid Neoplasms (Thyroid Cancer) 01/2018 - 01/2011
2	Multiple Endocrine Neoplasia Type 1 04/2011 - 01/2009
2	Carcinoma (Carcinomatosis) 05/2008 - 01/2005
1	Atherosclerosis 01/2022
1	Hypoxia (Hypoxemia) 01/2021
1	Gigantism 12/2020
1	Rare Diseases (Rare Disease) 04/2019
1	Cachexia 10/2016
1	Insulin Resistance 02/2016
1	Obesity 02/2016
1	Hypertension (High Blood Pressure) 01/2016
1	Pancreatic Neoplasms (Pancreatic Cancer) 03/2013
1	Carcinoid Tumor (Carcinoid) 08/2012
1	Familial Isolated Pituitary Adenoma 06/2012
1	Parathyroid Neoplasms (Parathyroid Neoplasm) 04/2011
1	Glucagonoma 01/2009
1	Smooth Muscle Tumor 05/2008

Drug/Important Bio-Agent (IBA)

5	Growth Hormone (Somatotropin)IBA 12/2020 - 01/2014
5	Proteins (Proteins, Gene)FDA Link 11/2015 - 03/2004
5	Cyclin-Dependent Kinase Inhibitor p27IBA 01/2015 - 07/2007
4	dactolisibIBA 01/2017 - 08/2011
3	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 06/2015 - 01/2011
3	DNA (Deoxyribonucleic Acid)IBA 04/2011 - 05/2003
2	LipidsIBA 01/2022 - 10/2016
2	Pharmaceutical PreparationsIBA 01/2022 - 06/2021
2	Everolimus FDA Link 01/2022 - 08/2011
2	Octreotide (Sandostatin)FDA LinkGeneric 06/2021 - 04/2019
2	pasireotideIBA 06/2021 - 04/2019
2	CatecholaminesIBA 01/2021 - 06/2015
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 04/2019 - 01/2011
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2016 - 01/2011
2	5' Untranslated Regions (5' UTR)IBA 05/2015 - 03/2013
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2015 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 07/2013 - 10/2010
1	Gemcitabine FDA Link 01/2022
1	Angiopoietin-2IBA 01/2022
1	Zoledronic Acid (Zometa)FDA Link 01/2022
1	Sunitinib (Sutent)FDA Link 01/2022
1	TIE-2 Receptor (Receptor, TIE 2)IBA 01/2022
1	AlpelisibIBA 01/2022
1	selpercatinibIBA 01/2022
1	trametinibIBA 01/2022
1	cabozantinibIBA 01/2022
1	niraparibIBA 01/2022
1	N- (4- methoxybenzyl)- N'- (5- nitro- 1,3- thiazol- 2- yl)ureaIBA 01/2022
1	entinostat (MS 275)IBA 01/2022
1	Oxygen (Dioxygen)IBA 01/2021
1	aryl hydrocarbon receptor-interacting proteinIBA 04/2019
1	Insulin-Like Growth Factor I (IGF-1)IBA 04/2019
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2018
1	Cytostatic AgentsIBA 01/2017
1	Uncoupling Protein 1IBA 10/2016
1	Peptides (Polypeptides)IBA 10/2016
1	AMP-Activated Protein KinasesIBA 10/2016
1	Glucose (Dextrose)FDA LinkGeneric 02/2016
1	GhrelinIBA 02/2016
1	NormetanephrineIBA 01/2016
1	Epinephrine (Adrenaline)FDA LinkGeneric 01/2016
1	MethyltransferasesIBA 01/2016
1	MetanephrineIBA 01/2016
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2015
1	ProlactinIBA 09/2015
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 09/2015
1	beta-DefensinsIBA 07/2015
1	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 06/2015
1	ParaffinIBA 06/2015
1	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2014
1	3-Iodobenzylguanidine (Iobenguane)IBA 12/2013
1	Steroidogenic Factor 1IBA 07/2013
1	Cholesterol Side-Chain Cleavage Enzyme (CYP11A1)IBA 07/2013
1	Folic Acid (Vitamin M)FDA LinkGeneric 04/2013
1	CyclinsIBA 01/2013
1	secretin receptorIBA 08/2012
1	Secretin FDA Link 08/2012
1	Bortezomib (Velcade)FDA Link 08/2011
1	Sirolimus (Rapamycin)FDA Link 08/2011
1	Proteasome InhibitorsIBA 08/2011
1	MTOR InhibitorsIBA 08/2011
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 08/2011
1	Ga(III)-DOTATOCIBA 01/2011
1	IncretinsIBA 01/2011
1	Edotreotide (SMT 487)IBA 01/2011
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2011
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2011
1	gastric inhibitory polypeptide receptorIBA 01/2011
1	Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA 10/2010
1	Mutant Proteins (Protein, Mutant)IBA 05/2010
1	Glucagon (Glukagon)FDA Link 01/2009

Therapy/Procedure

12	Therapeutics 01/2022 - 01/2011